CLINICAL TRIALS PROFILE FOR DIMETHYL FUMARATE
✉ Email this page to a colleague
All Clinical Trials for Dimethyl Fumarate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00420212 ↗ | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | Completed | Biogen | Phase 3 | 2007-01-01 | To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for the disease to get worse. The purpose of this study is also to determine the safety of BG00012 and how well it is tolerated. Another goal is to see what effect BG00012 may have on tests and evaluations used to assess MS. |
| NCT00451451 ↗ | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis | Completed | Biogen | Phase 3 | 2007-06-01 | To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse. Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012. |
| NCT00835770 ↗ | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | Completed | Biogen | Phase 3 | 2009-02-03 | The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test. |
| NCT01156311 ↗ | BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis | Completed | Biogen | Phase 2 | 2010-06-01 | The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting multiple sclerosis (RRMS). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Dimethyl Fumarate
Condition Name
| Condition Name for Dimethyl Fumarate | |
| Intervention | Trials |
| Multiple Sclerosis | 22 |
| Relapsing-Remitting Multiple Sclerosis | 13 |
| Multiple Sclerosis, Relapsing-Remitting | 12 |
| Relapsing Remitting Multiple Sclerosis | 6 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for Dimethyl Fumarate
Trials by Country
Clinical Trial Progress for Dimethyl Fumarate
Clinical Trial Phase
Clinical Trial Sponsors for Dimethyl Fumarate
Sponsor Name
